Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.